

800 000 pieces



Indication	Manufacturing base	Dosage form & Dosage
Treatment for chemotherapy-induced thrombocytopenia (CIT); Treatment for immune thrombocytopenia (ITP).	Shenyang manufacturing base	7500 U/1 ml; 15000 U/1 ml

200 000 pieces



Indication	Manufacturing base	Dosage form & Dosage
Treatment for advanced breast cancer in postmenopausal women; Treatment for early-stage breast cancer in postmenopausal women with positive hormone receptor.	Zhejiang manufacturing base	12.5 mg/bottle; 25 mg/bottle

1 500 000 pieces



Wanwei is a 5-HT3 receptor antagonist antiemetic drug used for vomiting caused by cytotoxic chemotherapy. Wanwei is the first listed generic product among the products of the same type after the original product was approved for import and marketed in China. Compared with other traditional medicines, Wanwei is highly efficient and selective, and can more effectively control delayed vomiting.

Indication	Manufacturing base	Dosage form & Dosage
Treatment for vomiting caused by cytotoxic chemotherapy;	Zhejiang manufacturing base	/

400 000 pieces



Indication	Manufacturing base	Dosage form & Dosage
Treatment for anemia caused by chronic kidney disease; Erythrocyte mobilization of peripheral operation; Treatment for anemia caused by chemotherapy.	Shenyang manufacturing base	Penicillin bottle - 2,000 IU/piece, 3,000 IU/piece, 4,000 IU/piece, 10,000 IU/piece, 36,000 IU/piece; Pre-filled syringe - 2,000 IU/piece, 3,000 IU/piece, 4,000 IU/piece, 10,000 IU/piece.

300 000 pieces



In April 1995, Intefen was approved to be manufactured by CFDA. In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.



Indication	Manufacturing base	Dosage form & Dosage
Treatment of lymphatic or hematopoietic malignancies and viral infections: adult chronic hepatitis B, acute and chronic hepatitis C and condyloma acuminata.	Shenyang manufacturing base	Injection - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml; Freeze-dried powder - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml.

300 000 pieces

英路因®



In June 1995, CFDA production approval documents were obtained for Inleusin. This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.

Indication

Treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis.

Manufacturing base
Shenyang manufacturing base

Dosage form & Dosage

100,000 IU/bottle; 200,000 IU/bottle; 500,000 IU/bottle; 1,000,000 IU/bottle

800 000 pieces



Indication

Treatment for anemia caused by chronic kidney disease;
Treatment for anemia caused by chemotherapy.

Manufacturing base
Shenzhen manufacturing base

Dosage form & Dosage

Penicillin bottle - 2000IU/1.0ml/piece, 2500IU/1.0ml/piece, 3000IU/1.0ml/piece, 4000IU/1.0ml/piece, 5000IU/1.0ml/piece, 10000IU/1.0ml/piece;
Pre-filled syringe - 2000IU/0.5ml/piece, 2500IU/0.5ml/piece, 3000IU/0.5ml/piece, 4000IU/0.5ml/piece, 5000IU/0.5ml/piece, 10000IU/0.5ml/piece (PFS).

2 000 000 pieces

迪苏®



Disu is a new and efficient bidirectional immunomodulator, mainly used for the prevention and treatment of chronic bronchitis, colds and asthma. Disu was included in the National Essential Medicines List.

Indication

For the prevention and treatment of chronic bronchitis, colds and asthma. Disu was included in the National Essential Medicines List.

Manufacturing base
Zhejiang manufacturing base

Dosage form & Dosage

/

3 000 000 pieces

爱益舒®
蔗糖铁注射液

Treatment of iron-deficiency anemia

Indication

Treatment of iron-deficiency anemia.

Manufacturing base
Shenyang manufacturing base

Dosage form & Dosage

/

5 000 000 pieces

蔓迪



Mandi is the first domestically-listed drug among the products of the same type and the first brand the products of the same type at home.

Indication

Mandi is used for the treatment of male-pattern alopecia and alopecia areata, and is the first non-prescription drug for hair loss

Manufacturing base
Zhejiang manufacturing base

Dosage form & Dosage

/

健尼派®



Jiannipai is suitable for prevention of acute rejection after renal transplantation, which can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.

Indication

The product is suitable for prevention of acute rejection after renal transplantation, which can be combined with the immunosuppression regime containing calcineurin inhibitors and corticosteroid hormone.

Manufacturing base
Shanghai manufacturing base

Dosage form & Dosage

25mg/5ml/vial

I have a huge market for these, what approvals have these received? Will you be interested in a distributorship, rebranding?